Technical analyst Hitesh Chotalia has maintained 'buy' rating on Cadila Healthcare Limited stock with a short term target of Rs 800.

According to analyst, the investors can purchase the stock with a stop loss of Rs 760.

The stock of the company, on December 14, closed at Rs 774.20 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 809.45 and a low of Rs 421.54 on BSE.

Current EPS & P/E ratio stood at 30.72 and 25.30 respectively.

On Dec 12, Zydus Cadila Healthcare said that it is eyeing to treble its income by 2015 on account of its growth in the novel market zones and technologies.

The company is looking at $3 billion revenue by the next five years as against $1 billion, which it that it targets to attain by March 2011.

For the three moth period ended Sep 2010, Cadila Healthcare has registered a growth of 29.50% in its consolidated net profit, which stood at Rs 1,708.4 million as compared to Rs 1,319.2 million in the corresponding period of last year.

The company net sales grew by 21.23% to Rs 11,063.2 million for the period under review as against Rs 9,125.8 million for the same period of 2009.

On standalone basis, the company's net profit remained at Rs 1,816 million for the three month period under review as against Rs 1,244 million for the same period of 2009

Total income surged 16.43% to Rs 7,627.10 million for the quarter ended Sep 2010.